DWP16001 0.3mg

DRUG3 trials

Sponsors

Daewoong Pharmaceutical Co. LTD.

Conditions

HealthyType 2 Diabetes MellitusType 2 Diabetic Nephropathy

Phase 1

Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy Adults

Not yet recruitingNCT06644404

Daewoong Pharmaceutical Co. LTD.Healthy

Start: 2024-10-26End: 2025-04-01Target: 34Updated: 2024-10-16

Phase 3

A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes Mellitus

RecruitingNCT05466643

Daewoong Pharmaceutical Co. LTD.Type 2 Diabetes Mellitus

Start: 2023-03-17End: 2024-09-30Target: 240Updated: 2024-04-08

Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients

Not yet recruitingNCT06606093

Daewoong Pharmaceutical Co. LTD.Type 2 Diabetic Nephropathy

Start: 2024-09-23End: 2027-01-31Target: 348Updated: 2024-09-20

Related Papers

Efficacy and Safety of Enavogliflozin as Add-on in Adults with Type 2 Diabetes Mellitus Inadequately Controlled with Insulin or Insulin with Other Antidiabetic Drugs.

2025-12-15